Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Videos>This Video
  Videos

Return

Preclinical Drug Safety: High Quality Data obtained with a New Automated Patch Clamp Platform
Select Biosciences Ltd

Many compounds have been reported to prolong the QT interval interfering with the hERG channel, leading to life-threatening cardiac arrhythmias. According to FDA guideline every drug going to market must be tested on the hERG channel. Due to this international regulation, there is a great demand for accurate hERG screens as well as for other pacemaker channels. Manual patch clamp is still the gold standard for investigation of ion channels, but throughput is low and a skilled operator is needed. Cytocentrics overcomes these problems by developing the CytoPatch™ Instrument. Thus outsourcing of patch clamp screening offers a true advantage to drug developing companies: Lowering their operating costs and having access to the latest technology and scientific expertise. As examples for the patch clamp quality of the CytoPatch™ Instrument we show that the electrophysiological and pharmacological properties of the cardiac potassium channels like hERG and kv1.5 investigated on the CytoPatch™ Instrument are in excellent agreement with data known from manual patch clamp: This demonstrates that ion channel screening on the CytoPatch™ Instrument delivers the same high data quality known from manual patch clamp at a throughput level required for safety pharmacology screening.

Request more information
Company product page

Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!